Apellis and Sobi Report Positive Top-line Results from the Phase 3 PRINCE Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Ads

You May Also Like

Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval

Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval London, UK – 28 August 2018: ...

Inovio Pharmaceuticals Reports 2018 Third Quarter Financial Results

PLYMOUTH MEETING, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a ...